17:36 , Jan 11, 2019 |  BC Week In Review  |  Company News

1st Biotherapeutics, twoXAR to use AI to discover glioblastoma candidates

1st Biotherapeutics Inc. (Seongnam, South Korea) and twoXAR Inc. (Mountain View, Calif.) partnered to discover and develop treatments for glioblastoma multiforme. twoXAR will use its AI technology to identify candidates, and both companies will determine...
00:00 , Jan 18, 2018 |  BioCentury  |  Emerging Company Profile

Computing brain entry

1st Biotherapeutics Inc. aims to develop a pipeline of first- or best-in-class molecules for CNS diseases by using computational tools to achieve better blood-brain barrier penetration and PK properties than marketed drugs against the same...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Company News

1ST Bio partners with Neuraly for PD

1ST Bio Therapeutics Inc. (Seongnam, South Korea) partnered with Neuraly Inc. to co-develop brain penetrant inhibitors of ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL; ABL1) to treat Parkinson's disease. Neuraly spun out of Johns Hopkins...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...